Albumin for Hepatocellular Carcinoma

• Status: Recruiting
• Trial end date: 2020-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The rate of liver cirrhosis is about 40% to 75% among patients with hepatocellular carcinoma (HCC). Therefore, many patients with HCC were with low serum albumin before and after (especially) hepatic resection. Serum albumin level has been routinely used in clinical practice as a surrogate marker to evaluate nutritional status and liver function. Serum albumin concentration is used as an independent mortality risk predictor in a broad range of clinical and research settings. However, the role of albumin infusion in patients with hepatocellular carcinoma (HCC) after resection is unknown. The present study aimed to investigate the safety and clinical necessity of albumin infusion for HCC patients after hepatic resection.

• Phase: Phase 3
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Guangxi Medical University

Criteria

Inclusion Criteria:

• Body mass index >18.5;

• Patients with primary hepatocellular carcinoma without any treatments for tumors before resection;

• Hepatocellular carcinoma should be confirmed by histopathology;

• With preserved liver function (Child-Pugh score ≤7) before resection

• ECOG performance score 0 or 1;

• Preoperative serum albumin >35g/L;

• The level of postoperative serum albumin is between 25-30g/L in the first day after resection.

Exclusion Criteria:

• Patients used albumin before liver resection (<1 months);

• Plasma was used during or after liver resection;

• Surgery involving the extrahepatic bile duct or gastrointestinal tract.